Filana Therapeutics, Inc. (FLNA)Healthcare | Biotechnology | Austin, United States | NasdaqCM
1.15 USD
-0.03
(-2.542%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.17 +0.02 (1.739%) ⇧ (July 13, 2026, 7:39 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:04 a.m. EDT
The investment case for Filana Therapeutics is severely compromised by a brutal multi-year decline. The company has lost over 86% of its value since 2016, and the last four consecutive years have been negative, culminating in an 80% drop last year. While the balance sheet shows a current ratio above 2 and positive free cash flow, these are insufficient to offset the structural deterioration evident in the price action and the crushing negative returns on equity. The lack of any dividend history confirms this is a pure growth/development play that has failed to deliver. Furthermore, the options market is screaming caution; the heavy concentration of put open interest suggests traders are betting against further declines or aggressively hedging existing long positions. With analysts offering a mean target of $6.50, there is a theoretical recovery path, but the persistent failure to generate positive annual returns makes this a high-risk speculative vehicle rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.074604 |
| AutoARIMA | 0.122569 |
| AutoETS | 0.175514 |
| MSTL | 0.189245 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.678 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2012-12-12 |
| Last Dividend Date | 2012-12-12 |
| Market Cap | 55,554,080 |
| Beta | -0.74 |
| Previous Name | Cassava Sciences, Inc. |
| Website | https://www.filanatx.com |
As of July 11, 2026, 3:04 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with massive volume and open interest concentrated in deep out-of-the-money puts for the 2028 expiration. This indicates a strong hedging bias or a bearish view that the stock could trade lower, despite some speculative call activity at strikes far above the current price.
| Date | Dividend | Yield % |
|---|---|---|
| 2012-12-13 | 5.25 | 29.644270 |
| 2010-12-13 | 14.00 | 30.395136 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4537037 |
| Address1 | 6,801 N. Capital of Texas Highway |
| Address2 | Building 1 |
| All Time High | 184.625 |
| All Time Low | 0.76 |
| Ask | 1.24 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 399,150 |
| Average Daily Volume3 Month | 401,142 |
| Average Volume | 401,142 |
| Average Volume10Days | 399,150 |
| Beta | -0.737 |
| Bid | 1.32 |
| Bid Size | 3 |
| Book Value | 1.411 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.15 |
| Current Ratio | 2.193 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.18 |
| Day Low | 1.125 |
| Display Name | Filana Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -48,713,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.637 |
| Enterprise Value | -31,018,920 |
| Eps Trailing Twelve Months | -1.57 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,355,356,800 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3044 |
| Fifty Day Average Change | -0.15439999 |
| Fifty Day Average Change Percent | -0.118368596 |
| Fifty Two Week Change Percent | -45.37037 |
| Fifty Two Week High | 4.98 |
| Fifty Two Week High Change | -3.83 |
| Fifty Two Week High Change Percent | -0.7690763 |
| Fifty Two Week Low | 1.125 |
| Fifty Two Week Low Change | 0.024999976 |
| Fifty Two Week Low Change Percent | 0.0222222 |
| Fifty Two Week Range | 1.125 - 4.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 963,581,400,000 |
| Float Shares | 47,317,584 |
| Free Cashflow | 16,069,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -17,468,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.020499999 |
| Held Percent Institutions | 0.28722998 |
| Implied Shares Outstanding | 48,307,896 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.paintrials.com/stockquote.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,355,356,800 |
| Last Dividend Value | 5.25 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,494,374,400 |
| Last Split Factor | 1:7 |
| Long Business Summary | Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas. |
| Long Name | Filana Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 55,554,080 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_107567 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -77,901,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 57,486,396 |
| Number Of Analyst Opinions | 2 |
| Open | 1.21 |
| Operating Cashflow | -29,794,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.62 |
| Phone | 512 501 2444 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 1.7391288 |
| Post Market Price | 1.17 |
| Post Market Time | 1,783,985,959 |
| Prev Name | Cassava Sciences, Inc. |
| Previous Close | 1.18 |
| Price Hint | 4 |
| Price To Book | 0.8150248 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.161 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -2.54237 |
| Regular Market Day High | 1.18 |
| Regular Market Day Low | 1.125 |
| Regular Market Day Range | 1.125 - 1.18 |
| Regular Market Open | 1.21 |
| Regular Market Previous Close | 1.18 |
| Regular Market Price | 1.15 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 304,233 |
| Return On Assets | -0.24906 |
| Return On Equity | -0.79589 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 48,307,896 |
| Shares Percent Shares Out | 0.13430001 |
| Shares Short | 6,489,283 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,885,919 |
| Short Name | Filana Therapeutics, Inc. |
| Short Percent Of Float | 0.1371 |
| Short Ratio | 19.7 |
| Source Interval | 15 |
| State | TX |
| Symbol | FLNA |
| Target High Price | 8.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.5 |
| Target Median Price | 6.5 |
| Total Cash | 86,573,000 |
| Total Cash Per Share | 1.792 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.23105 |
| Two Hundred Day Average Change | -1.08105 |
| Two Hundred Day Average Change Percent | -0.48454764 |
| Type Disp | Equity |
| Volume | 304,233 |
| Website | https://www.filanatx.com |
| Zip | 78,731 |